Cargando…

Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

OBJECTIVES: We investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of evacetrapib. METHODS: Healthy volunteers received multiple daily doses of evacetrapib (10–600 mg) administered for up to 15 days in a placebo-controlled study. KEY FINDINGS: Mean peak plasma concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suico, Jeffrey G, Wang, Ming-Dauh, Friedrich, Stuart, Cannady, Ellen A, Konkoy, Christopher S, Ruotolo, Giacomo, Krueger, Kathryn A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Ltd 2014
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284021/ https://www.ncbi.nlm.nih.gov/pubmed/24961753 http://dx.doi.org/10.1111/jphp.12287

Ejemplares similares

CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015)

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects
por: Small, David S., et al.
Publicado: (2016)

Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors
por: Cannady, Ellen A, et al.
Publicado: (2015)

A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State
por: Small, David S., et al.
Publicado: (2015)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13)C(8)]‐evacetrapib as a tracer
por: Cannady, Ellen A., et al.
Publicado: (2015)

Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins
Publicado: (1979)

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
por: Menon, Venu, et al.
Publicado: (2020)

The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)

Lipoprotein-heparin-fibronectin-denatured collagen complexes enhance cholesteryl ester accumulation in macrophages
Publicado: (1984)

Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
por: Kettunen, Johannes, et al.
Publicado: (2019)

Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease
por: Furtado, Jeremy D., et al.
Publicado: (2021)

Correction: Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
por: Kettunen, Johannes, et al.
Publicado: (2020)

Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia
por: Poliakova, Tetiana, et al.
Publicado: (2023)

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels
por: Nelson, Adam J., et al.
Publicado: (2022)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

CETP inhibitor evacetrapib enters mouse brain tissue
por: Phénix, Jasmine, et al.
Publicado: (2023)

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
por: Chapman, M. John, et al.
Publicado: (2010)

Particle number analysis of lipoprotein subclasses by gel permeation HPLC in patients with cholesteryl ester transfer protein deficiency
por: Okada, Takeshi, et al.
Publicado: (2018)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
por: Thomas, Tiffany, et al.
Publicado: (2017)

Assessing the mechanisms of cholesteryl ester transfer protein inhibitors
por: Zhang, Meng, et al.
Publicado: (2017)

Oxidized Low-Density Lipoproteins Trigger Hepatocellular Oxidative Stress with the Formation of Cholesteryl Ester Hydroperoxide-Enriched Lipid Droplets
por: Sazaki, Iku, et al.
Publicado: (2023)

Concentration dependent cholesteryl-ester and wax-ester structural relationships and meibomian gland dysfunction
por: Hetman, Zofia A., et al.
Publicado: (2020)

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib
por: Goldberg, Alyse S, et al.
Publicado: (2012)

Cholesteryl Ester Transfer Protein Gene Polymorphisms and Longevity Syndrome
por: Kolovou, Genovefa, et al.
Publicado: (2010)

Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
por: Mabuchi, Hiroshi, et al.
Publicado: (2014)

Fluorescent Sterols and Cholesteryl Esters as Probes for Intracellular Cholesterol Transport
por: Solanko, Katarzyna A., et al.
Publicado: (2016)

Structure-based mechanism and inhibition of cholesteryl ester transfer protein
por: Xue, Han, et al.
Publicado: (2023)

Low density lipoprotein receptor-related protein 1 expression correlates with cholesteryl ester accumulation in the myocardium of ischemic cardiomyopathy patients
por: Cal, Roi, et al.
Publicado: (2012)

High-Density Lipoprotein (HDL) Particle Subpopulations in Heterozygous Cholesteryl Ester Transfer Protein (CETP) Deficiency: Maintenance of Antioxidative Activity
por: Chantepie, Sandrine, et al.
Publicado: (2012)

Low‐density lipoprotein receptor is required for cholesteryl ester transfer protein to regulate triglyceride metabolism in both male and female mice
por: Palmisano, Brian T., et al.
Publicado: (2021)

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells
por: Benitez-Amaro, Aleyda, et al.
Publicado: (2022)

Females with angina pectoris have altered lipoprotein metabolism with elevated cholesteryl ester transfer protein activity and impaired high-density lipoproteins-associated antioxidant enzymes
por: PARK, JUNGHO, et al.
Publicado: (2011)

Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2010)

Cholesteryl Esters Accumulate in the Heart in a Porcine Model of Ischemia and Reperfusion
por: Drevinge, Christina, et al.
Publicado: (2013)

The Proteome of Cholesteryl-Ester-Enriched Versus Triacylglycerol-Enriched Lipid Droplets
por: Khor, Victor K., et al.
Publicado: (2014)

Cholesteryl ester transfer protein: ace of spades, queen of hearts, or the joker?
por: Miller, Norman E.
Publicado: (2015)

REVEAL Study: Reveals the Limitations of Cholesteryl Ester Transfer Protein Inhibition
por: Pareek, Anil, et al.
Publicado: (2018)

Cholesterol is Inefficiently Converted to Cholesteryl Esters in the Blood of Cardiovascular Disease Patients
por: Gerl, Mathias J., et al.
Publicado: (2018)

Cholesteryl ester levels are elevated in the caudate and putamen of Huntington’s disease patients
por: Phillips, Gabrielle R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m3q7mlscn22u8gs89fiml328vj